Track topics on Twitter Track topics that are important to you
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/01/15 -- Aurora Cannabis Inc. (CSE: ACB)(FRANKFURT: 21P)(WKN: A1C4WM)(OTC PINK: PSNTF) ("Aurora" or the "Company) announces that on June 22, 2015, it will be presenting at the Inaugural Canadian Cannabis Conference presented by Jacob Securities.
Terry Booth, CEO of Aurora, will be speaking to the advantages and challenges of the most recently approved licensed producers.
Leslie Bocskor, Managing Partner of Electrum Partners, will be speaking to the American Cannabis market and the regulatory environments in key states including what opportunities these jurisdictions present. Electrum Partners are partners via a consultant contract with Aurora's entry into the American Cannabis market.
The Canadian Cannabis Conference is a must attend forum for those considering investment in this industry with a global perspective. Presentations and panel discussion will include cross border investing, developments in the MMPR program, industry consolidation, patient acquisition initiatives, research and development, extraction status and distribution and retail.
For more details on the conference agenda and other aspects of the conference including reservations, please visit www.jacobsecurities.com/conference.
Aurora will be available for one on one meetings during the conference. Please reserve your spot by contacting Elise Coppens at email@example.com.
About Aurora Cannabis Inc.
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora's wholly-owned subsidiary, Australis Capital Inc. is pursuing a number of synergetic opportunities in the U.S. Cannabis market.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.Contacts: Investor Relations: Paul J. Searle Toll Free: 1-844-928-7672 Media Inquiries: Elise Coppens Marketing Director Toll Free: 1-844-928-7672 NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...